Provided by Tiger Fintech (Singapore) Pte. Ltd.

ATAI Life Sciences B.V.*

4.17
+0.07001.71%
Post-market: 4.15-0.0200-0.48%19:57 EDT
Volume:7.68M
Turnover:31.24M
Market Cap:884.64M
PE:-4.60
High:4.28
Open:4.00
Low:3.82
Close:4.10
Loading ...

Atai Life Sciences announces $50M private placement

TIPRANKS
·
01 Jul

Atai Life Sciences, Beckley Psytech report positive Phase 2b results of BPL-003

TIPRANKS
·
01 Jul

Press Release: atai Life Sciences Announces $50 Million Private Placement Financing

Dow Jones
·
01 Jul

ATAI Life Sciences NV Announces Positive Phase 2b Results for BPL-003, Advancing Toward Phase 3 Trials for Treatment-Resistant Depression

Reuters
·
01 Jul

ATAI Life Sciences (ATAI) Gets a Buy from H.C. Wainwright

TIPRANKS
·
01 Jul

ATAI Life Sciences Down Over 16%, on Pace for Largest Percent Decrease Since January 2023 -- Data Talk

Dow Jones
·
24 Jun

Atai Life Sciences initiated with a Buy at Lucid Capital

TIPRANKS
·
06 Jun

ATAI Life Sciences and Beckley Psytech Merger: Strategic Moves and Promising Pipeline Justify Buy Rating

TIPRANKS
·
06 Jun

Strategic Merger and Financial Strength Propel ATAI Life Sciences to ‘Buy’ Rating

TIPRANKS
·
02 Jun

ATAI Life Sciences Announces Share Purchase Agreement

TIPRANKS
·
02 Jun

ATAI Life Sciences and Beckley Psytech Announce Definitive Agreement to Merge in Strategic All-Share Transaction

Reuters
·
02 Jun

Press Release: atai Life Sciences and Beckley Psytech to Combine Creating a Global Leader in Psychedelic Mental Health Therapies

Dow Jones
·
02 Jun

ATAI Life Sciences NV Files Initial Statement of Beneficial Ownership for Director John Francis Hoffman

Reuters
·
24 May

ATAI Life Sciences Approves Key Governance Changes

TIPRANKS
·
22 May

ATAI Life Sciences NV Conducted Annual Shareholders Meeting

Reuters
·
22 May

TD Cowen Reaffirms Their Buy Rating on ATAI Life Sciences (ATAI)

TIPRANKS
·
21 May

ATAI Life Sciences: Promising Clinical Data and Strategic Investments Drive Buy Rating

TIPRANKS
·
21 May

Atai Life Sciences Reports Positive Phase 2a Results for Treatment-Resistant Depression Drug

MT Newswires Live
·
20 May

ATAI Life Sciences Price Target Maintained With a $10.00/Share by HC Wainwright & Co.

Dow Jones
·
20 May

Atai Life Sciences announces data from Part 2 of Phase 2a study of BPL-003

TIPRANKS
·
20 May